```
Welcome to STN International! Enter x:x
LOGINID:sssptaaal1614
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2
* * * * * * * * * * Welcome to STN International
NEWS
                 Web Page for STN Seminar Schedule - N. America
NEWS
         JAN 02
                 STN pricing information for 2008 now available
NEWS
         JAN 16
                 CAS patent coverage enhanced to include exemplified
                 prophetic substances
NEWS
         JAN 28
                 USPATFULL, USPAT2, and USPATOLD enhanced with new
                 custom IPC display formats
NEWS 5
         JAN 28
                 MARPAT searching enhanced
NEWS 6
         JAN 28
                 USGENE now provides USPTO sequence data within 3 days
                 of publication
         JAN 28
                 TOXCENTER enhanced with reloaded MEDLINE segment
NEWS
NEWS 8
         JAN 28 MEDLINE and LMEDLINE reloaded with enhancements
NEWS 9 FEB 08
                 STN Express, Version 8.3, now available
NEWS 10 FEB 20 PCI now available as a replacement to DPCI
NEWS 11 FEB 25
                 IFIREF reloaded with enhancements
NEWS 12 FEB 25
                 IMSPRODUCT reloaded with enhancements
NEWS 13 FEB 29 WPINDEX/WPIDS/WPIX enhanced with ECLA and current
                 U.S. National Patent Classification
                 IFICDB, IFIPAT, and IFIUDB enhanced with new custom
NEWS 14 MAR 31
                 IPC display formats
NEWS 15
         MAR 31
                 CAS REGISTRY enhanced with additional experimental
NEWS 16 MAR 31
                 CA/CAplus and CASREACT patent number format for U.S.
                 applications updated
NEWS 17 MAR 31
                 LPCI now available as a replacement to LDPCI
NEWS 18 MAR 31
                 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 19 APR 04
                 STN AnaVist, Version 1, to be discontinued
                 WPIDS, WPINDEX, and WPIX enhanced with new
NEWS 20 APR 15
                 predefined hit display formats
NEWS 21 APR 28 EMBASE Controlled Term thesaurus enhanced
NEWS 22 APR 28
                 IMSRESEARCH reloaded with enhancements
NEWS 23 MAY 30
                 INPAFAMDB now available on STN for patent family
                 searching
NEWS 24 MAY 30
                 DGENE, PCTGEN, and USGENE enhanced with new homology
                 sequence search option
NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
             AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008
NEWS HOURS
              STN Operating Hours Plus Help Desk Availability
              Welcome Banner and News Items
NEWS LOGIN
NEWS IPC8
              For general information regarding STN implementation of IPC 8
```

Enter NEWS followed by the item number or name to see news on that

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 16:13:30 ON 04 JUN 2008

=>

Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE Do you want to switch to the Registry File?

Choice (Y/n):

Switching to the Registry File...

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 0.21 0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 16:14:00 ON 04 JUN 2008 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ${\tt ZIC/VINITI}$ data file provided by InfoChem.

STRUCTURE FILE UPDATES: 3 JUN 2008 HIGHEST RN 1025148-33-7 DICTIONARY FILE UPDATES: 3 JUN 2008 HIGHEST RN 1025148-33-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>

Uploading C:\Program Files\Stnexp\Queries\10797795 clm17.str

chain nodes :

7 8 9 10 11 12 13 14

ring nodes :

1 2 3 4 5 6

chain bonds :

4-14 5-7 7-8 7-13 8-9 9-10 10-11 10-12

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

7-13 8-9 9-10 10-11 10-12

exact bonds:

4-14 5-7 7-8 normalized bonds:

1-2 1-6 2-3 3-4 4-5 5-6

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS

L1 STRUCTURE UPLOADED

=> dis

L1 HAS NO ANSWERS

L1 STR

Structure attributes must be viewed using STN Express query preparation.

=> s L1 full

A. A. Lewis

FULL SEARCH INITIATED 16:14:23 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1819 TO ITERATE

100.0% PROCESSED 1819 ITERATIONS 7 ANSWERS

SEARCH TIME: 00.00.01

L2 7 SEA SSS FUL L1

=> file hcap

COST IN U.S. DOLLARS

FULL ESTIMATED COST ENTRY SESSION 178.36 178.57

SINCE FILE

TOTAL

FILE 'HCAPLUS' ENTERED AT 16:14:38 ON 04 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 4 Jun 2008 VOL 148 ISS 23 FILE LAST UPDATED: 3 Jun 2008 (20080603/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s L2

L3 41 L2

=> s L3 and (ischemia or neurodegener)

) IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system. For a list of commands available to you in the current file, enter "HELP COMMANDS" at an arrow prompt (=>).

=> s L3 and (ischemi? or neurodegenerat?)

97721 ISCHEMI?

209 ISCHEM

209 ISCHEM

(ISCHEM)

97750 ISCHEMI?

(ISCHEMI? OR ISCHEM)

28301 NEURODEGENERAT?

L4 5 L3 AND (ISCHEMI? OR NEURODEGENERAT?)

=> d L4 1-5 ibib abs hitstr

L4 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN

A. A. Lewis

ACCESSION NUMBER: 2008:528301 HCAPLUS

DOCUMENT NUMBER: 148:487225

TITLE: Carbamate compounds for treatment of cochlear and

vestibular disorders

INVENTOR(S):
Haas, Magali

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 31pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

GΙ

PA:	PATENT NO.						DATE			APPL	ICAT	DATE					
US	2008	0103	 198		A1	_	2008	0501		US 2	007-	8705	11		2	0071	011
WO	2008	0607	87		A2		2008	0522	,	WO 2	007-1	US81	031		2	0071	011
	W:	ΑE,	AG,	AL,	AM,	ΑT,	ΑU,	ΑZ,	BA,	BB,	BG,	BH,	BR,	BW,	BY,	BZ,	CA,
		CH,	CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DO,	DZ,	EC,	EE,	EG,	ES,	FI,
		GB,	GD,	GE,	GH,	GM,	GT,	HN,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,
		KM,	KN,	KP,	KR,	KΖ,	LA,	LC,	LK,	LR,	LS,	LT,	LU,	LY,	MA,	MD,	ME,
		MG,	MK,	MN,	MW,	MX,	MY,	MZ,	NA,	NG,	NΙ,	NO,	NZ,	OM,	PG,	PH,	PL,
		PT,	RO,	RS,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SM,	SV,	SY,	ТJ,	TM,	TN,
		TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	ZA,	ZM,	ZW				
	RW:	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FΙ,	FR,	GB,	GR,	HU,	ΙE,
		IS,	ΙΤ,	LT,	LU,	LV,	MC,	MT,	NL,	PL,	PT,	RO,	SE,	SI,	SK,	TR,	BF,
		ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG,	BW,
		GH,	GM,	ΚE,	LS,	MW,	MΖ,	NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	ΑM,	ΑZ,
		BY,	KG,	KΖ,	MD,	RU,	ТJ,	TM									
PRIORITY	Y APP	LN.	INFO	.:						US 2	006-	8631	44P]	P 2	0061	027

AB This invention is directed to methods for providing otoprotection comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of Formula (I) and Formula (II) or a pharmaceutically acceptable salt or ester

ΙI

thereof where X = F, Cl, Br, or I; R1-R6 = H or C1-C4 alkyl (un)substituted with Ph, etc.

IT 194085-73-9 194085-73-9D, enantiomers, salts, and esters

194085-75-1 194085-75-1D, salts and esters

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(carbamate compds. for treatment of cochlear and vestibular disorders)

RN 194085-73-9 HCAPLUS

CN 1,2-Ethanediol, 1-(2-chlorophenyl)-, 2-carbamate (CA INDEX NAME)

RN 194085-73-9 HCAPLUS

CN 1,2-Ethanediol, 1-(2-chlorophenyl)-, 2-carbamate (CA INDEX NAME)

RN 194085-75-1 HCAPLUS

CN 1,2-Ethanediol, 1-(2-chlorophenyl)-, 2-carbamate, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

RN 194085-75-1 HCAPLUS

CN 1,2-Ethanediol, 1-(2-chlorophenyl)-, 2-carbamate, (1S)- (CA INDEX NAME)

L4 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:61845 HCAPLUS

DOCUMENT NUMBER: 146:135588

TITLE: Neuroprotective carbamate derivatives for treatment of

neurodegenerative disorders

INVENTOR(S): Zhao, Boyu; Tywman, Roy E.

PATENT ASSIGNEE(S): Janssen Pharmaceutica, N.V., Belg.

SOURCE: PCT Int. Appl., 83pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

					KIND DATE					APPL	-							
WO	2007 2007	0085	62		A2		2007	0118					20060707					
	W:	ΑE,	AG,	AL,	AM,	ΑT,	AU,	ΑZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,	
							DE,											
		GE,	GH,	GM,	HN,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	KM,	KN,	KP,	
		KR,	KΖ,	LA,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	LY,	MA,	MD,	MG,	MK,	MN,	
		MW,	MX,	MZ,	NA,	NG,	NΙ,	NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RS,	RU,	
		SC,	SD,	SE,	SG,	SK,	SL,	SM,	SY,	ΤJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	
		US,	UΖ,	VC,	VN,	ZA,	ZM,	ZW										
	RW:	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	HU,	IE,	
		IS,	ΙΤ,	LT,	LU,	LV,	MC,	NL,	PL,	PT,	RO,	SE,	SI,	SK,	TR,	BF,	ВJ,	
		CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	ML,	MR,	ΝE,	SN,	TD,	ΤG,	BW,	GH,	
		GM,	ΚE,	LS,	MW,	MΖ,	NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	ΑM,	ΑZ,	BY,	
		•		•			TM,	•										
US	2007	0021	500		A1		2007	0125		US 2	006-	4816	01		20060706			
													20060707					
												20060707						
EP	1917																	
	R:				•		CZ,							•			•	
		IS,	IT,	LI,	LT,	LU,	LV,	MC,	NL,	PL,	PT,	RO,	SE,	SI,	SK,	TR,	AL,	
			HR,															
	KR 2008031951						2008	0411								0080		
PRIORIT:	ORITY APPLN. INFO.:													P 20050712				
									WO 2006-US26291						W 20060707			
OTHER SO	HER SOURCE(S):					MARPAT 146:135588												

GΙ

AB This invention is directed to methods for providing neuroprotection comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from Formula (I) and Formula (II), where Ph is substituted at X with 1-5 halo atoms selected from F, C, B or I and R1-R6 = (un)substituted C1-C4 alkyl or pharmaceutical acceptable salts or esters thereof. Carbamate derivative decreased infarct volume following reperfusion in a rat model of transient cerebral ischemia arising from middle cerebral artery occlusion.

IT 194085-75-1

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(neuroprotective carbamate derivs. for treatment of neurodegenerative disorders)

RN 194085-75-1 HCAPLUS

CN 1,2-Ethanediol, 1-(2-chlorophenyl)-, 2-carbamate, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

L4 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:383992 HCAPLUS

DOCUMENT NUMBER: 144:404414

TITLE: Carbamate compounds for use in treating

neurodegenerative disorders

INVENTOR(S): Twyman, Roy E.; Zhao, Boyu

PATENT ASSIGNEE(S): Janssen Pharmaceutica, N.V., Belg.

SOURCE: PCT Int. Appl., 91 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PA:	ΓΕΝΤ	NO.			KIN	D	DATE			APPL	ICAT	ION I	DATE						
WO 2006044472					A1	_	2006	0427	,	WO 2	005-	US36	 695		20051014				
	W:	ΑE,	AG,	AL,	AM,	ΑT,	ΑU,	ΑZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,		
		CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,		
		GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	KM,	KP,	KR,	KΖ,		
		LC,	LK,	LR,	LS,	LT,	LU,	LV,	LY,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,		
		NA,	NG,	ΝI,	NO,	NΖ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,		
		SK,	SL,	SM,	SY,	ТJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,		
		YU,	ZA,	ZM,	ZW														
	RW:	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	HU,	ΙE,		
		IS,	ΙT,	LT,	LU,	LV,	MC,	NL,	PL,	PT,	RO,	SE,	SI,	SK,	TR,	BF,	ΒJ,		
		CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	ML ,	MR,	ΝE,	SN,	TD,	TG,	BW,	GH,		
		GM,	KΕ,	LS,	MW,	MΖ,	NΑ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	ΑM,	ΑZ,	BY,		
		KG,	KΖ,	MD,	RU,	ТJ,	$_{ m TM}$												
AU 2005295787					A1		2006	0427		AU 2005-295787						20051014			
CA	2584	854			A1		20060427		1	CA 2005-2584854						20051014			

EP	1802	294			A1	2	2007	0704		ΕP	20	2	20051014					
	R:	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	ΕE	Ξ,	ES,	FI,	FR,	GB,	GR,	HU,	IE,
		IS,	ΙΤ,	LI,	LT,	LU,	LV,	MC,	NL,	PΙ	٠,	PT,	RO,	SE,	SI,	SK,	TR,	AL,
		ΒA,	HR,	MK,	ΥU													
CN	1010	7632	7		Α	2	2007	1121	1	CN	20	05-	80042	2469		2	0051	014
JP	2008	5169	61		Τ	2	2008	0522		JΡ	20	07-	5368	43		2	0051	014
SG	142306				A1	2	2008	3528		SG	20	008-	2877			2	0051	014
МX	2007	0449	1		Α	2	2007	8080		MΧ	20	07-	4491			2	0070	413
NO	2007	0024	44		Α	2	2007	0614		ИО	20	07-	2444			2	0070	511
KR	2007	0853	09		Α	2	2007	0827		KR	20	07-	7107	44		2	0070	511
IN	2007	KN01	701		Α	2	2007	727		ΙN	20	07-1	KN170	01		2	0070	514
PRIORITY	Y APP	LN.	INFO	.:						US	20	004-	61940	02P		P 2	0041	015
										US	20	05-0	69840	03P		P 2	0050	712
									,	WO	20	05-1	JS36	695	1	W 2	0051	014

OTHER SOURCE(S): MARPAT 144:404414 GI

AB The invention discloses methods for providing neuroprotection, comprising administering to a subject in need thereof a therapeutically effective amount of a compound I or II [Ph is substituted at X with 1-5 halo atoms selected from F, Cl, Br, I; Rl-R6 = H, (un)substituted Cl-C4 alkyl], or a pharmaceutically acceptable salt or ester thereof.

IT 194085-75-1

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (carbamate compds. for neuroprotectants)

RN 194085-75-1 HCAPLUS

CN 1,2-Ethanediol, 1-(2-chlorophenyl)-, 2-carbamate, (1S)- (CA INDEX NAME)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:333530 HCAPLUS

DOCUMENT NUMBER: 144:324867

TITLE: Methods of treating epileptogenesis and epilepsy Choi, Yong Moon; Gordon, Robert; Novak, Gerald P.; INVENTOR(S):

Plata-Salaman, Carlos R.; Twyman, Roy E.; White, H.

Steve; Zhao, Boyu

PATENT ASSIGNEE(S): Janssen Pharmaceutica, N.V., Belg.

SOURCE: PCT Int. Appl., 111 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PA	PATENT NO.						KIND DATE					CAT		DATE				
	2006						2006			WO				861		2	0050	915
WO	2006	0339	47		А3		2006	0629										
	W:	ΑE,	AG,	AL,	ΑM,	ΑT,	ΑU,	ΑZ,	BA,	BE	3, E	ЗG,	BR,	BW,	BY,	BΖ,	CA,	CH,
		CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ	Z, E	EC,	EE,	EG,	ES,	FΙ,	GB,	GD,
		GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	ΙS	5, J	JP,	ΚE,	KG,	KM,	KP,	KR,	KΖ,
		LC,	LK,	LR,	LS,	LT,	LU,	LV,	LY,	MA	A, M	ΊD,	MG,	MK,	MN,	MW,	MX,	MZ,
		NA,	NG,	NΙ,	NO,	NZ,	OM,	PG,	PH,	PΙ	., P	РΤ,	RO,	RU,	SC,	SD,	SE,	SG,
		SK,	SL,	SM,	SY,	ТJ,	TM,	TN,	TR,	ΤT	., I	Z,	UA,	UG,	US,	UΖ,	VC,	VN,
		YU,	ZA,	ZM,	ZW													
	RW:	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE	., E	ES,	FI,	FR,	GB,	GR,	HU,	ΙE,
		IS,	ΙT,	LT,	LU,	LV,	MC,	NL,	PL,	PΊ	, R	Ю,	SE,	SI,	SK,	TR,	BF,	ВJ,
		CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	MI	., M	ΊR,	ΝE,	SN,	TD,	ΤG,	BW,	GH,
		GM,	ΚE,	LS,	MW,	MZ,	NA,	SD,	SL,	SZ	, I	Z,	UG,	ZM,	ZW,	ΑM,	AZ,	BY,
		KG,	KΖ,	MD,	RU,	ТJ,	TM											
AU	2005	2871	74		A1		2006	0330		AU	200)5-2	2871	74		2	0050	915
CA	2580	640			A1		2006	0330		CA	200)5-2	2580	640		2	0050	915
US	2006	0194	873		A1		2006	0831		US	200)5-2	2272	47		2	0050	915
EP							EP 2005-810288							0050				
	R:	ΑT,	BE,	ВG,	CH,	CY,	CZ,	DE,	DK,	EE	:, E	ES,	FI,	FR,	GB,	GR,	HU,	ΙE,
		IS,	IT,	LI,	LT,	LU,	LV,	MC,	NL,	PΙ	, P	РΤ,	RO,	SE,	SI,	SK,	TR,	AL,
		BA,	HR,	MK,	YU													
CN	1010	5662	9		Α		2007	1017		CN	200	5-8	3003	8741		2	0050	915
JP	2008	5134					2008	0501		JP 2007-532446						2	0050	915
			8		Α		2007	1008		MX 2007-3278						2	0070	316
IN	2007	KN00'	999		Α		2007	0713		IN	200)7-E	KN99!	9		2	0070	321
KR	2007	0579.	39		A		2007	0607		KR	200	7-	7084	02		2	0070	413
ИО	2007	0019			A		2007	0612		NO 2007-1921						20070416		
PRIORIT	LC, LK, NA, NG, SK, SL, YU, ZA, RW: AT, BE, IS, IT, CF, CG, GM, KE, KG, KZ, AU 2005287174 CA 2580640 US 20060194873 EP 1809273 R: AT, BE, IS, IT, BA, HR, CN 101056629 JP 2008513466 MX 200703278 IN 2007KN00999 KR 2007057939 NO 2007001921 IORITY APPLN. INFO									US	200	4-6	5102	76P		P 2	0040	916
														25P		P 2	0050	712
										US	200)5-T	7072	42P			0050	811
										WO	200)5-t	JS32	861	•	W 2	0050	915
OTHER S	HER SOURCE(S):					MARPAT 144:32486												

OTHER SOURCE(S): MARPAT 144:324867

This invention is directed to methods for preventing, treating, reversing, inhibiting or arresting epilepsy and epileptogenesis in a subject comprising administering to the subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of Formula (I) and Formula (II), or a pharmaceutically acceptable salt or ester thereof,: Formula (I) Formula (II) wherein Ph is substituted at X with one to five halogen atoms selected from the group consisting of fluorine,

chlorine, bromine and iodine; and, R1, R2, R3, R4, R5 and R6 are independently selected from the group consisting of hydrogen and C1-C4 alkyl; wherein C1-C4 alkyl is optionally substituted with Ph (wherein Ph is optionally substituted with substituents independently selected from the group consisting of halogen, C1-C4 alkyl, C1-C4 alkoxy, amino, nitro and cyano).

IT 194085-73-9 194085-73-9D, ester derivs.

194085-75-1 194085-75-1D, ester derivs.

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(treating epileptogenesis and epilepsy)

RN 194085-73-9 HCAPLUS

CN 1,2-Ethanediol, 1-(2-chlorophenyl)-, 2-carbamate (CA INDEX NAME)

RN 194085-73-9 HCAPLUS

CN 1,2-Ethanediol, 1-(2-chlorophenyl)-, 2-carbamate (CA INDEX NAME)

RN 194085-75-1 HCAPLUS

CN 1,2-Ethanediol, 1-(2-chlorophenyl)-, 2-carbamate, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

RN 194085-75-1 HCAPLUS

CN 1,2-Ethanediol, 1-(2-chlorophenyl)-, 2-carbamate, (1S)- (CA INDEX NAME)

L4 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:675829 HCAPLUS

DOCUMENT NUMBER: 137:179913

TITLE: Phenyl carbamate compounds for use in preventing or

treating neurodegenerative disorders

INVENTOR(S): Plata-Salaman, Carlos R.; Zhao, Boyu; Twyman, Roy E.

PATENT ASSIGNEE(S): Ortho-McNeil Pharmaceutical, Inc., USA

SOURCE: PCT Int. Appl., 34 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PA.	TENT	NO.			KIN	D	DATE			APPI	ICAT	DATE						
WO	2002	0679	 25		A1	_	2002	0906		WO 2	2002-		20020221					
	W:	ΑE,	AG,	AL,	ΑM,	ΑT,	ΑU,	AΖ,	BA,	BB,	BG,	BR,	BY,	BΖ,	CA,	CH,	CN,	
		CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	
		GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KΕ,	KG,	KP,	KR,	KΖ,	LC,	LK,	LR,	
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	OM,	PH,	
							SE,			SK,	SL,	ΤJ,	TM,	TN,	TR,	TT,	TZ,	
		UA,	UG,	UZ,	VN,	YU,	ZA,	ZM,	ZW									
	RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	ΑT,	BE,	CH,	
		CY,	DE,	DK,	ES,	FΙ,	FR,	GB,	GR,	ΙE,	ΙΤ,	LU,	MC,	NL,	PT,	SE,	TR,	
		BF,	ΒJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	$ ext{ML}$,	MR,	ΝE,	SN,	TD,	ΤG	
							20020906 CA 2002-2439295											
ΑU	2002		A1		2002	0912		AU 2	2002-		20020221							
US	US 20020165273 EP 1383489						2002	1107		US 2	2002-	8176	4		2	0020	221	
EΡ	EP 1383489						2004	0128		EP 2	2002-	7149	77		2	0020	221	
EP	1383	489			В1		2007	0509										
	R:	•	•	•			ES,	•	•		•	LI,	LU,	ΝL,	SE,	MC,	PT,	
			,			,	RO,	,	•	,					_			
	2003						2004				2003-			0020				
	1503				A		2004				2002-							
	2004						2004				2002-		20020221					
	2002		45				2004				2002-		20020221					
	5279				A		2006	-			2002-	-				0020		
	2300				T		2007				2003-		_	0020				
	3617	-			т Т3		2007				2002-	-			0020			
_	2284	-	0.0				2007	_		-	2002-	_				0020 0030		
	2003				A						2003-		_	0030				
	2003				A A		2004				2003- 2003-					0030		
		2003KN01225 A 2005 2003007473 A 2005									:003- :003-		23					
	2003		-		A A1		2003				.003- :004-		۵E		20030925 20040310			
	1060		0/9		A1		2004				:004- :004-				20040310			
													-			$0040 \\ 0041$	-	
1117	1000	1065486 A1 20060901 HK 2004-108387											_	0041	020			

PRIORITY APPLN. INFO.: US 2001-271682P P 20010227 US 2002-81764 A 20020221

WO 2002-US5541 W 20020221

OTHER SOURCE(S): MARPAT 137:179913

ΙI

GΙ

$$\begin{array}{c|c}
0 & R3 \\
 & N & R4 \\
 & R5 \\
 & N & R6
\end{array}$$

AΒ This invention is directed to a method for preventing or treating neurodegenerative disorders comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of formula I and formula II, wherein X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and, R1-R6 are independently selected from the group consisting of hydrogen and C1-C4 alkyl; wherein C1-C4 alkyl is optionally substituted with Ph (wherein Ph is optionally substituted with substituents independently selected from the group consisting of halogen, C1-C4 alkyl, C1-C4 alkoxy, amino, nitro and cyano). The neurodegenerative disorders are selected from the group consisting of acute neurodegenerative disorders, chronic neurodegenerative disorders, other acute or chronic neurodegenerative disorders associated with memory loss and other acute or chronic neurodegenerative disorders associated with neuronal injury. The chronic neurodegenerative disorders are selected from Alzheimer's disease, chronic epileptic conditions associated with neurodegeneration, multiple sclerosis or Parkinson's disease. Thus, title I and II (X = ortho-Cl, R1-R6 = H) were tested in rats for treatment of neurodegenerative disorders. The therapeutically effective amount is from about 0.01~mg/Kg/dose to about 100~mg/Kg/dosema/Ka/dose.

IT 194085-75-1

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(Ph carbamate compds. for use in preventing or treating neurodegenerative disorders)

RN 194085-75-1 HCAPLUS

CN 1,2-Ethanediol, 1-(2-chlorophenyl)-, 2-carbamate, (1S)- (CA INDEX NAME)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 16:13:30 ON 04 JUN 2008)

FILE 'REGISTRY' ENTERED AT 16:14:00 ON 04 JUN 2008

L1 STRUCTURE UPLOADED

L2 7 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 16:14:38 ON 04 JUN 2008

L3 41 S L2

L4 5 S L3 AND (ISCHEMI? OR NEURODEGENERAT?)

=> d que

L1 STR

Structure attributes must be viewed using STN Express query preparation.

L2 7 SEA FILE=REGISTRY SSS FUL L1

L3 41 SEA FILE=HCAPLUS ABB=ON PLU=ON L2

L4 5 SEA FILE=HCAPLUS ABB=ON PLU=ON L3 AND (ISCHEMI? OR NEURODEGEN ERAT?)

=> log off hold

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 16:23:39 ON 04 JUN 2008